Publication | Closed Access

mTOR inhibitor, gemcitabine and PD-L1 antibody blockade combination therapy suppresses pancreatic cancer progression via metabolic reprogramming and immune microenvironment remodeling in Trp53flox/+LSL-KrasG12D/+Pdx-1-Cre murine models

Cancer ImmunosurveillancePancreatic CancerMedicineImmunologyTrp53flox/+lsl-krasg12d/+pdx-1-cre Murine ModelsImmune Checkpoint InhibitorMtor InhibitorPancreatic Cancer ProgressionImmunotherapyCancer MetabolismCell BiologyTumor Microenvironment